[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@onco_park Byung-June Park
Byung-June Park posts on X about $4528t, bios, the only the most. They currently have XXXXX followers and XXX posts still getting attention that total X engagements in the last XX hours.
Engagements: X #
- X Week XX -XX%
- X Month XXXXX +299%
- X Months XXXXX -XX%
- X Year XXXXXXX +47%
Mentions: X #
- X Week X no change
- X Month XX -XX%
- X Months XX -XX%
- X Year XXX +20%
Followers: XXXXX #
- X Week XXXXX no change
- X Month XXXXX +0.21%
- X Months XXXXX +3.40%
- X Year XXXXX +43%
CreatorRank: undefined #
Social Influence #
Social topic influence $4528t, bios, the only
Top Social Posts #
Top posts by engagements in the last XX hours
"FT825/ONO-8250 a HER2 CAR-T cell therapy co-developed by Fate Therapeutics and ONO PHARMACEUTICAL and now in Phase X trials incorporates advanced engineering techniques. The challenge in HER2 CAR-T development extends beyond merely applying CAR-T cell therapy to solid tumors; it must address the unmet medical needs associated with HER2-targeting agents like T-DXd. Key priorities include overcoming potential resistance to T-DXd and achieving higher tumor cell specificity than existing HER2-targeting drugs. At #SITC24 FT825/ONO-8250 emphasized its preferential targeting of HER2-expressing"
X Link @onco_park 2024-11-09T21:11Z 2359 followers, 2288 engagements
"#ASCO24 #CD137 Selecting the optimal indications for PD-L14-1BB bispecific TCEs can be very challenging. Genmab's Acasunlimab is being developed for R/R NSCLC the only indication where it has shown multiple responses as a monotherapy. Applying the same logic Merus's MCLA-145 would be developed for GI cancer and I-Mab/ABL Bio's ragistomig for PROC. Can the hints we've observed in some clinical trials provide a rational basis for setting the late-stage clinical strategy for this class of drugs"
X Link @onco_park 2024-06-02T18:46Z 2360 followers, 1188 engagements